The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C, Ortiz MDA, Moya P, Hernandez MV, Reina D, Castellvi I, De Agustin JJ, Fuente D, Corominas H, Sanmarti R, Zamora C, Cantó E, Vidal S.
Diaz-Torne C, et al. Among authors: fuente d.
Semin Arthritis Rheum. 2018 Jun;47(6):757-764. doi: 10.1016/j.semarthrit.2017.10.022. Epub 2017 Nov 20.
Semin Arthritis Rheum. 2018.
PMID: 29157669